This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Thiotepa and Radiation Therapy in Treating Young Patients With Newly Diagnosed Malignant Brain Tumors

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2006 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: April 11, 2006
Last updated: September 19, 2013
Last verified: December 2006

RATIONALE: Drugs used in chemotherapy, such as thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy and radiation therapy after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II trial is studying how well thiotepa works together with radiation therapy in treating young patients with newly diagnosed malignant brain tumors.

Condition Intervention Phase
Brain and Central Nervous System Tumors Drug: thiotepa Procedure: adjuvant therapy Radiation: radiation therapy Phase 2

Study Type: Interventional
Study Design: Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Continuous Infusion Thiotepa in High Grade Astrocytic Tumors of Childhood and Adolescence A UKCCSG Phase II Study Involving the Brain Tumour and New Agent Groups

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Degree of surgical resection by surgical and radiological assessments

Secondary Outcome Measures:
  • Tumor response to chemotherapy by imaging

Estimated Enrollment: 30
Study Start Date: June 1995
Estimated Primary Completion Date: November 1997 (Final data collection date for primary outcome measure)
Detailed Description:



  • Determine tumor response to adjuvant thiotepa followed by radiotherapy in pediatric patients with newly diagnosed malignant astrocytic tumors.


  • Determine the acute and chronic toxicity of thiotepa in these patients.
  • Determine the variability in thiotepa metabolism by measuring plasma and cerebrospinal fluid pharmacokinetics of thiotepa and tepa in these patients.
  • Develop a phase II study framework model, to determine the chemosensitivity to new, single-agent regimens in the treatment of high-grade (malignant) astrocytic tumors, including anaplastic astrocytoma, glioblastoma, giant cell glioblastoma, and gliosarcoma.
  • Determine the incidence of distant neuraxial metastases in patients at the time of relapse.
  • Determine the 1-year disease-free survival rate in patients treated with this regimen.

OUTLINE: This is a multicenter study. Patients are stratified by age (3-15 vs 16-20 years of age).

  • Chemotherapy: Patients receive thiotepa IV continuously over 168 hours on days 1-7. Treatment repeats every 28 days for up to 2 courses. Patients then proceed to radiotherapy after blood counts recover.
  • Radiotherapy: Patients undergo external-beam radiotherapy once daily, 5 days a week, for approximately 6 weeks.
  • Post-radiation chemotherapy: Patients with complete, partial, or objective response, or stable disease after 2 courses of thiotepa may receive thiotepa alone for up to 8 more courses at the discretion of the treating physician.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.


Ages Eligible for Study:   3 Years to 20 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed diagnosis of 1 of the following high-grade (malignant) astrocytic tumors:

    • Anaplastic astrocytoma
    • Glioblastoma
    • Giant cell glioblastoma
    • Gliosarcoma
  • Any anatomical site except brain stem
  • Newly diagnosed disease
  • Has undergone tumor biopsy or surgical resection within the past 2 weeks

    • Patients with post-operative residual disease (grade III or IV) are eligible

      • Post-operative imaging of tumor within 72 hours of surgery
    • Patients with no imageable post-operative disease are not eligible
  • No neurological deterioration within 3 days of study treatment

    • Increasing requirement for steroids to control symptoms of intracranial pressure is considered evidence of neurological deterioration


  • Lansky play score 40-100%
  • Absolute neutrophil count > 1,000/mm^3
  • Platelet count > 100,000/mm^3
  • Creatinine ≥ 1.5 times upper limit of normal


  • See Disease Characteristics
  • No prior chemotherapy or radiotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00313521

Sponsors and Collaborators
Children's Cancer and Leukaemia Group
Study Chair: David A. Walker Queen's Medical Centre
  More Information Identifier: NCT00313521     History of Changes
Other Study ID Numbers: CDR0000454503
Study First Received: April 11, 2006
Last Updated: September 19, 2013

Keywords provided by National Cancer Institute (NCI):
untreated childhood cerebellar astrocytoma
childhood high-grade cerebral astrocytoma

Additional relevant MeSH terms:
Brain Neoplasms
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on September 21, 2017